O‘RTA DARAJADAGI AKNE VULGARISDA PAST DOZALI IZOTRETINOIN VA MAHALLIY NIATSINAMID KOMBINATSIYASINING SAMARADORLIGI: RANDOMIZATSIYALANGAN NAZORATLI SINOV
Keywords:
Kalit so‘zlar: akne vulgaris, izotretinoin, niatsinamid, past dozali retinoid, randomizatsiyalangan nazorat ostidagi sinov, dermatologiya.Abstract
ANNOTATSIYA
Dolzarbligi. Akne vulgaris dunyoda eng ko‘p uchraydigan dermatologik
kasalliklardan biri bo‘lib qolmoqda, biroq o‘rta darajadagi kasallik uchun optimal
davolash protokoli hozirgacha munozarali masala hisoblanadi. Standart dozadagi
izotretinoin yuqori samaradorlikka ega bo‘lsa-da, u sezilarli nojo‘ya ta’sirlar bilan
bog‘liq bo‘lib, bu uning qo‘llanilishini cheklaydi.
Maqsad. O‘rta darajadagi akne vulgarisi bo‘lgan bemorlarda past dozali
izotretinoin bilan mahalliy 4% niatsinamid kombinatsiyasining klinik samaradorligi va
tolerantligini standart dozadagi izotretinoin monoterapiyasi bilan solishtirib baholash.
Materiallar va metodlar. 24 haftalik randomizatsiyalangan nazorat ostidagi
sinovga 16–35 yoshdagi, o‘rta darajadagi akne (IGA bo‘yicha 3-ball) tashxisi
qo‘yilgan 128 nafar ishtirokchi jalb etildi. A guruh (n=64) izotretinoinni 0,2 mg/kg/kun
dozasida hamda kuniga ikki marta mahalliy 4% niatsinamid kremi bilan birgalikda
qabul qildi; B guruh (n=64) izotretinoinni 0,5 mg/kg/kun standart dozasida qabul qildi.
Asosiy natija ko‘rsatkichlari sifatida 12- va 24-haftalarda Investigator Global
Assessment (IGA) bali va yallig‘lanishli elementlar sonining kamayishi baholandi.
Natijalar. 24-haftada har ikkala guruhda ham yallig‘lanishli elementlar sonining
sezilarli darajada kamayishi kuzatildi: A guruhda o‘rtacha 78,4%, B guruhda 81,2%
(p=0,43), bu esa noinferiorlik mezoniga javob berdi. A guruhda nojo‘ya ta’sirlar,
xususan xeylit (23,4% ga qarshi 62,5%, p<0,001) va teri qurishi (18,8% ga qarshi
54,7%, p<0,001) sezilarli darajada kamroq qayd etildi.
Xulosa. Past dozali izotretinoin bilan mahalliy niatsinamid kombinatsiyasi
standart dozadagi monoterapiyaga solishtirma samaradorlikka ega bo‘lib, ancha yuqori
tolerantlik profilini ta’minlaydi va o‘rta darajadagi akne davolashda istiqbolli
alternativa hisoblanadi.
References
ADABIYOTLAR RO‘YXATI
1. Tan J.K.L., Bhate K. A global perspective on the epidemiology of acne // Br. J. Dermatol.
— 2015. — Vol. 172, Suppl. 1. — P. 3–12. doi:10.1111/bjd.13462
2. Halvorsen J.A., Stern R.S., Dalgard F., Thoresen M., Bjertness E., Lien L. Suicidal
ideation, mental health problems, and social impairment are increased in adolescents with
acne: a population-based study // J. Invest. Dermatol. — 2011. — Vol. 131, № 2. — P.
363–370. doi:10.1038/jid.2010.264
3. Layton A.M., Dreno B., Gollnick H.P., Zouboulis C.C. A review of the European
Directive for prescribing systemic isotretinoin for acne vulgaris // J. Eur. Acad. Dermatol.
Venereol. — 2006. — Vol. 20, № 7. — P. 773–784. doi:10.1111/j.1468-
3083.2006.01631.x
4. Chivot M. Retinoid therapy for acne. A comparative review // Am. J. Clin. Dermatol. —
2005. — Vol. 6, № 1. — P. 13–19. doi:10.2165/00128071-200506010-00002
5. Wohlrab J., Kreft D. Niacinamide – mechanisms of action and its topical use in
dermatology // Skin Pharmacol. Physiol. — 2014. — Vol. 27, № 6. — P. 311–315.
doi:10.1159/000360204
6. Borghi A., Mantovani L., Minghetti S., Virgili A., Bettoli V. Low-cumulative dose
isotretinoin treatment in mild-to-moderate acne: efficacy in achieving stable remission //
J. Eur. Acad. Dermatol. Venereol. — 2011. — Vol. 25, № 9. — P. 1094–1098.
doi:10.1111/j.1468-3083.2010.03918.x
7. Rademaker M. Isotretinoin: dose, duration and relapse. What does 30 years of usage tell
us? // Australas. J. Dermatol. — 2013. — Vol. 54, № 3. — P. 157–162.
doi:10.1111/ajd.12024
8. Quereux G., Volteau C., N'Guyen J.M., Dreno B. Prospective study of risk factors of
relapse after treatment of acne with oral isotretinoin // Dermatology. — 2006. — Vol. 212,
№ 2. — P. 168–176. doi:10.1159/000090661
